885 related articles for article (PubMed ID: 22710579)
1. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy.
Agrawal A; Sharma BC; Sharma P; Sarin SK
Am J Gastroenterol; 2012 Jul; 107(7):1043-50. PubMed ID: 22710579
[TBL] [Abstract][Full Text] [Related]
2. Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose.
Sharma P; Sharma BC; Agrawal A; Sarin SK
J Gastroenterol Hepatol; 2012 Aug; 27(8):1329-35. PubMed ID: 22606978
[TBL] [Abstract][Full Text] [Related]
3. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo.
Sharma BC; Sharma P; Agrawal A; Sarin SK
Gastroenterology; 2009 Sep; 137(3):885-91, 891.e1. PubMed ID: 19501587
[TBL] [Abstract][Full Text] [Related]
4. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy.
Sharma P; Sharma BC; Puri V; Sarin SK
Eur J Gastroenterol Hepatol; 2008 Jun; 20(6):506-11. PubMed ID: 18467909
[TBL] [Abstract][Full Text] [Related]
5. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy.
Mittal VV; Sharma BC; Sharma P; Sarin SK
Eur J Gastroenterol Hepatol; 2011 Aug; 23(8):725-32. PubMed ID: 21646910
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of abnormal psychometric tests and critical flicker frequency after clinical recovery of overt hepatic encephalopathy.
Sharma P; Sharma BC; Sarin SK
Neurol India; 2010; 58(2):220-4. PubMed ID: 20508339
[TBL] [Abstract][Full Text] [Related]
7. Predictors of nonresponse to lactulose for minimal hepatic encephalopathy in patients with cirrhosis.
Sharma P; Sharma BC; Sarin SK
Liver Int; 2009 Oct; 29(9):1365-71. PubMed ID: 19555401
[TBL] [Abstract][Full Text] [Related]
8. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial.
Lunia MK; Sharma BC; Sharma P; Sachdeva S; Srivastava S
Clin Gastroenterol Hepatol; 2014 Jun; 12(6):1003-8.e1. PubMed ID: 24246768
[TBL] [Abstract][Full Text] [Related]
9. Can Lactobacillus acidophilus improve minimal hepatic encephalopathy? A neurometabolite study using magnetic resonance spectroscopy.
Ziada DH; Soliman HH; El Yamany SA; Hamisa MF; Hasan AM
Arab J Gastroenterol; 2013 Sep; 14(3):116-22. PubMed ID: 24206740
[TBL] [Abstract][Full Text] [Related]
10. Critical flicker frequency for diagnosis and assessment of recovery from minimal hepatic encephalopathy in patients with cirrhosis.
Sharma P; Sharma BC; Sarin SK
Hepatobiliary Pancreat Dis Int; 2010 Feb; 9(1):27-32. PubMed ID: 20133225
[TBL] [Abstract][Full Text] [Related]
11. Lactulose is highly potential in prophylaxis of hepatic encephalopathy in patients with cirrhosis and upper gastrointestinal bleeding: results of a controlled randomized trial.
Wen J; Liu Q; Song J; Tong M; Peng L; Liang H
Digestion; 2013; 87(2):132-8. PubMed ID: 23485720
[TBL] [Abstract][Full Text] [Related]
12. Neuropsychological impairment in severe acute viral hepatitis is due to minimal hepatic encephalopathy.
Sharma P; Sharma BC; Tyagi P; Kumar M; Sarin SK
Liver Int; 2009 Feb; 29(2):260-4. PubMed ID: 18710429
[TBL] [Abstract][Full Text] [Related]
13. [Effects of lactulose treatment on the course of subclinical hepatic encephalopathy].
Zeng Z; Li YY
Zhonghua Yi Xue Za Zhi; 2003 Jul; 83(13):1126-9. PubMed ID: 12921628
[TBL] [Abstract][Full Text] [Related]
14. Lactulose for minimal hepatic encephalopathy in patients with extrahepatic portal vein obstruction.
Sharma P; Sharma BC
Saudi J Gastroenterol; 2012; 18(3):168-72. PubMed ID: 22626795
[TBL] [Abstract][Full Text] [Related]
15. Predictors of nonresponse to lactulose in patients with cirrhosis and hepatic encephalopathy.
Sharma P; Sharma BC; Sarin SK
Eur J Gastroenterol Hepatol; 2010 May; 22(5):526-31. PubMed ID: 20009938
[TBL] [Abstract][Full Text] [Related]
16. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy.
Prasad S; Dhiman RK; Duseja A; Chawla YK; Sharma A; Agarwal R
Hepatology; 2007 Mar; 45(3):549-59. PubMed ID: 17326150
[TBL] [Abstract][Full Text] [Related]
17. Serum endotoxin, inflammatory mediators, and magnetic resonance spectroscopy before and after treatment in patients with minimal hepatic encephalopathy.
Jain L; Sharma BC; Srivastava S; Puri SK; Sharma P; Sarin S
J Gastroenterol Hepatol; 2013 Jul; 28(7):1187-93. PubMed ID: 23425082
[TBL] [Abstract][Full Text] [Related]
18. Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver: a double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo.
Varakanahalli S; Sharma BC; Srivastava S; Sachdeva S; Dahale AS
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):951-958. PubMed ID: 29727385
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.
Kircheis G; Nilius R; Held C; Berndt H; Buchner M; Görtelmeyer R; Hendricks R; Krüger B; Kuklinski B; Meister H; Otto HJ; Rink C; Rösch W; Stauch S
Hepatology; 1997 Jun; 25(6):1351-60. PubMed ID: 9185752
[TBL] [Abstract][Full Text] [Related]
20. Prophylaxis of hepatic encephalopathy in acute variceal bleed: a randomized controlled trial of lactulose versus no lactulose.
Sharma P; Agrawal A; Sharma BC; Sarin SK
J Gastroenterol Hepatol; 2011 Jun; 26(6):996-1003. PubMed ID: 21129028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
